Clinic
Sentara RMH Medical Center
Sentara RMH Medical Center was paid $52.95M by Medicaid between Jan 2018 and Dec 2024, across 386 billing codes. Its largest line is 99283, emergency room visit (moderate) — 16% of everything it billed.
33Billing provider infoSENTARA RMH MEDICAL CENTER
HARRISONBURG, VA 22801
HARRISONBURG, VA 22801
33aNPI1780694372assigned 08/08/2006
33bProvider typeCardiac Rehabilitation Clinic/Center
28Total paid$52.95M
24GClaims1,544,385
24DCodes billed386
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Cardiac Rehabilitation Clinic/Center providers in Virginia
Rank by total paid#3 of 6
Median peer was paid$52.40M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HANCOCK, MELINDA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 182,997 | $3.79M | |
| 2019 | 237,447 | $5.38M | |
| 2020 | 200,386 | $6.14M | |
| 2021 | 228,060 | $7.15M | |
| 2022 | 224,338 | $8.44M | |
| 2023 | 261,177 | $11.31M | |
| 2024incomplete | 209,980 | $10.74M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 53,337 | 45,831 | $8.55M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 38,882 | 31,821 | $5.77M |
| 96361 | Intravenous infusion, hydration; each additional hour | 8.1% | 18,044 | 12,804 | $4.30M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.3% | 23,546 | 18,654 | $3.36M |
| 41899 | Unlisted procedure, dentoalveolar structures | 4.4% | 1,622 | 1,571 | $2.33M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.1% | 14,604 | 13,108 | $2.17M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.7% | 42,125 | 10,590 | $1.97M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.5% | 9,583 | 8,273 | $1.85M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.9% | 8,937 | 7,449 | $1.53M |
| G0378 | Hospital observation service, per hour | 1.8% | 4,689 | 3,367 | $930K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.6% | 1,602 | 1,470 | $829K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.5% | 2,882 | 2,549 | $774K |
374 more codes
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.3% | 1,333 | $711K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 3,797 | $697K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.3% | 6,361 | $684K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.3% | 7,004 | $679K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.3% | 2,863 | $666K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.0% | 2,243 | $551K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.0% | 5,372 | $532K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,453 | $480K |
| 62323 | <1% | 1,262 | $473K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,793 | $473K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 6,167 | $465K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,252 | $445K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 758 | $441K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 3,902 | $413K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 2,081 | $388K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,561 | $373K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 21,828 | $356K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,805 | $318K |
| 97162 | <1% | 2,738 | $289K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,307 | $285K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 16,733 | $282K |
| 0240U | <1% | 4,207 | $256K | |
| 97161 | <1% | 3,281 | $245K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 8,319 | $242K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 18,883 | $224K |
| 72141 | <1% | 1,152 | $205K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 11,441 | $203K |
| 76642 | <1% | 2,025 | $200K | |
| 93971 | <1% | 2,201 | $191K | |
| 59025 | Fetal non-stress test | <1% | 972 | $183K |
| 80053 | Comprehensive metabolic panel | <1% | 46,235 | $180K |
| J3490 | Unclassified drugs | <1% | 179,370 | $173K |
| 93976 | <1% | 1,684 | $169K | |
| 93017 | <1% | 1,873 | $157K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,813 | $156K |
| 20610 | <1% | 2,057 | $154K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 278 | $145K |
| 73562 | <1% | 4,938 | $137K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,608 | $135K |
| 70496 | <1% | 538 | $135K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 41,224 | $134K |
| 47562 | <1% | 41 | $130K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,682 | $127K |
| 72100 | <1% | 4,471 | $112K | |
| 73030 | <1% | 5,072 | $111K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,496 | $109K |
| 73110 | <1% | 4,006 | $107K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,340 | $97K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,188 | $93K |
| 73610 | <1% | 4,685 | $93K | |
| 59050 | <1% | 445 | $91K | |
| 76536 | <1% | 793 | $88K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 29,256 | $86K |
| 73630 | <1% | 4,568 | $86K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,269 | $85K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 14,156 | $77K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,718 | $77K |
| 71250 | <1% | 1,203 | $73K | |
| 73130 | <1% | 3,504 | $73K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 2,198 | $73K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 58,763 | $70K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 31,605 | $66K |
| 74018 | <1% | 3,126 | $66K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,552 | $63K |
| 12001 | <1% | 301 | $62K | |
| 95806 | <1% | 292 | $60K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 657 | $60K |
| 73221 | <1% | 373 | $60K | |
| 85027 | <1% | 33,170 | $59K | |
| 71045 | Radiologic examination, chest; single view | <1% | 22,613 | $58K |
| 73564 | <1% | 3,514 | $57K | |
| 73502 | <1% | 3,142 | $56K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 49 | $55K |
| 73140 | <1% | 1,989 | $53K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 501 | $49K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 691 | $48K |
| 76770 | <1% | 442 | $47K | |
| 73080 | <1% | 2,105 | $46K | |
| 94726 | <1% | 916 | $45K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,129 | $44K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 89 | $44K |
| 93970 | <1% | 364 | $43K | |
| 72050 | <1% | 1,204 | $43K | |
| 93922 | <1% | 654 | $40K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 2,226 | $40K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 17,734 | $37K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 5,587 | $37K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,202 | $37K |
| 80061 | Lipid panel | <1% | 8,267 | $36K |
| 83880 | <1% | 5,326 | $36K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 513 | $36K |
| 97113 | <1% | 748 | $36K | |
| 29125 | <1% | 346 | $35K | |
| 97597 | <1% | 773 | $34K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 25,543 | $32K |
| 96415 | <1% | 139 | $31K | |
| 97163 | <1% | 612 | $31K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,237 | $30K |
| 97165 | <1% | 497 | $29K | |
| 97116 | <1% | 2,123 | $28K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,813 | $28K |
| 85379 | <1% | 7,145 | $28K | |
| 64493 | <1% | 42 | $28K | |
| 84484 | <1% | 26,463 | $28K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,433 | $27K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 104 | $27K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 210 | $26K |
| 94010 | <1% | 761 | $26K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 72 | $26K |
| 73590 | <1% | 1,491 | $25K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,140 | $24K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 145 | $23K |
| 87040 | <1% | 5,535 | $23K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,546 | $22K |
| 94729 | <1% | 1,139 | $20K | |
| 90715 | <1% | 1,176 | $20K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 18,686 | $20K |
| 95816 | <1% | 78 | $19K | |
| 71271 | <1% | 181 | $19K | |
| 82607 | <1% | 2,898 | $19K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 686 | $19K |
| 73560 | <1% | 925 | $18K | |
| 70486 | <1% | 507 | $18K | |
| 84439 | <1% | 3,325 | $18K | |
| 77002 | <1% | 531 | $17K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 166 | $17K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 15,078 | $17K |
| 82728 | <1% | 3,936 | $17K | |
| 12011 | <1% | 81 | $16K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 14 | $16K |
| 81001 | <1% | 37,114 | $16K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 941 | $15K |
| 94060 | <1% | 561 | $15K | |
| 80076 | <1% | 10,191 | $14K | |
| 80047 | <1% | 3,637 | $14K | |
| 73090 | <1% | 691 | $13K | |
| 76870 | <1% | 149 | $13K | |
| 86140 | <1% | 4,528 | $12K | |
| 81025 | <1% | 16,938 | $12K | |
| 10060 | <1% | 84 | $12K | |
| 72072 | <1% | 547 | $12K | |
| 86850 | <1% | 3,586 | $11K | |
| 87631 | <1% | 465 | $11K | |
| 70498 | <1% | 548 | $11K | |
| 97802 | <1% | 158 | $11K | |
| 11045 | <1% | 22 | $11K | |
| 93880 | <1% | 129 | $11K | |
| 87634 | <1% | 668 | $11K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 938 | $10K |
| 72040 | <1% | 410 | $10K | |
| 86901 | <1% | 5,410 | $10K | |
| 82962 | <1% | 19,563 | $10K | |
| 93296 | <1% | 1,363 | $10K | |
| 77065 | Tomosynthesis, mammo | <1% | 261 | $10K |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 93 | $10K |
| 84112 | <1% | 339 | $9K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,544 | $9K |
| 85610 | <1% | 6,738 | $9K | |
| 83516 | <1% | 844 | $8K | |
| 62321 | <1% | 14 | $8K | |
| 80143 | <1% | 1,916 | $8K | |
| 83735 | <1% | 8,288 | $8K | |
| 99234 | <1% | 264 | $8K | |
| 86803 | <1% | 844 | $8K | |
| 70491 | <1% | 72 | $7K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 871 | $7K |
| 83550 | <1% | 3,139 | $7K | |
| 94799 | <1% | 2,191 | $7K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12,650 | $7K |
| 82746 | <1% | 1,592 | $7K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 20,121 | $7K |
| 83690 | <1% | 17,604 | $6K | |
| 86235 | <1% | 481 | $6K | |
| 88342 | <1% | 994 | $6K | |
| 85652 | <1% | 4,563 | $6K | |
| 83540 | <1% | 3,236 | $6K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,546 | $6K |
| 87077 | <1% | 6,110 | $6K | |
| 87186 | <1% | 5,169 | $6K | |
| 96367 | <1% | 153 | $6K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 16 | $5K |
| 84702 | <1% | 2,975 | $5K | |
| 87081 | <1% | 2,018 | $5K | |
| 96376 | <1% | 7,947 | $5K | |
| 85730 | <1% | 3,076 | $5K | |
| 86900 | <1% | 5,405 | $5K | |
| 12002 | <1% | 29 | $5K | |
| 82784 | <1% | 731 | $4K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 179 | $4K |
| 72120 | <1% | 141 | $4K | |
| 83605 | <1% | 5,342 | $4K | |
| 76801 | <1% | 159 | $4K | |
| 82565 | <1% | 2,597 | $4K | |
| 84153 | <1% | 512 | $4K | |
| 80179 | <1% | 1,863 | $4K | |
| 74019 | <1% | 143 | $4K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,644 | $4K |
| J0897 | Injection, denosumab, 1 mg | <1% | 15 | $4K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 674 | $4K |
| 74178 | <1% | 12 | $3K | |
| 82043 | <1% | 1,463 | $3K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,479 | $3K |
| 90686 | <1% | 326 | $3K | |
| 86618 | <1% | 275 | $3K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 16 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,761 | $3K |
| 84100 | <1% | 3,382 | $3K | |
| 70320 | <1% | 1,041 | $3K | |
| 86703 | <1% | 309 | $3K | |
| 87210 | <1% | 1,998 | $3K | |
| 85014 | <1% | 3,378 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 21,457 | $2K |
| 81003 | <1% | 6,951 | $2K | |
| 87070 | <1% | 2,365 | $2K | |
| 71101 | <1% | 348 | $2K | |
| 72070 | <1% | 188 | $2K | |
| 86160 | <1% | 365 | $2K | |
| 85018 | <1% | 1,903 | $2K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 2,735 | $2K |
| 88304 | <1% | 795 | $2K | |
| 86431 | <1% | 523 | $2K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 6,612 | $2K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,512 | $2K |
| 84703 | <1% | 4,071 | $2K | |
| 86225 | <1% | 330 | $2K | |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | <1% | 12 | $2K |
| 86038 | <1% | 262 | $2K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 13 | $2K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 16 | $2K |
| 84550 | <1% | 868 | $2K | |
| 94760 | <1% | 9,112 | $1K | |
| 84481 | <1% | 263 | $1K | |
| 82550 | <1% | 1,240 | $1K | |
| 96523 | <1% | 41 | $1K | |
| 87340 | <1% | 341 | $1K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 285 | $1K |
| 76882 | <1% | 15 | $1K | |
| 87449 | <1% | 460 | $1K | |
| 77336 | <1% | 53 | $1K | |
| 80050 | General health panel | <1% | 186 | $1K |
| 87522 | Neg quan hep c or qual rna | <1% | 56 | $1K |
| 74246 | <1% | 12 | $1K | |
| 87427 | <1% | 356 | $1K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 781 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,349 | $1K |
| 83970 | <1% | 58 | $1K | |
| 76775 | <1% | 16 | $1K | |
| 87205 | <1% | 2,554 | $1K | |
| 80164 | <1% | 168 | $1K | |
| 72131 | <1% | 12 | $1K | |
| 82077 | <1% | 4,194 | $1K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,419 | $1K |
| G0008 | Administration of influenza virus vaccine | <1% | 219 | $965.33 |
| 92610 | <1% | 13 | $955.72 | |
| 86200 | <1% | 206 | $951.75 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,541 | $942.31 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,569 | $941.99 |
| 73660 | <1% | 33 | $904.20 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,334 | $872.27 |
| 82570 | <1% | 304 | $865.23 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,602 | $857.70 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,896 | $836.21 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 1,664 | $829.19 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 354 | $789.62 |
| 72170 | <1% | 69 | $786.30 | |
| 87045 | <1% | 378 | $709.14 | |
| 73552 | <1% | 82 | $681.14 | |
| J2704 | Injection, propofol, 10 mg | <1% | 7,688 | $645.82 |
| 87899 | <1% | 171 | $642.62 | |
| 82785 | <1% | 69 | $641.30 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 443 | $614.96 |
| 86039 | <1% | 109 | $609.72 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 30 | $609.13 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 389 | $591.00 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,147 | $583.92 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,414 | $577.24 |
| 77080 | <1% | 27 | $576.06 | |
| 84145 | <1% | 527 | $532.84 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,717 | $527.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 519 | $510.86 |
| J3535 | Drug administered through a metered dose inhaler | <1% | 365 | $508.87 |
| 84403 | <1% | 41 | $507.33 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 342 | $431.40 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 215 | $380.34 |
| 86147 | <1% | 35 | $346.68 | |
| 86705 | <1% | 68 | $339.76 | |
| 82805 | <1% | 618 | $329.11 | |
| 82247 | <1% | 42 | $317.91 | |
| 97803 | <1% | 13 | $315.78 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 480 | $313.79 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,418 | $305.14 |
| 82803 | <1% | 646 | $285.71 | |
| 73060 | <1% | 65 | $278.02 | |
| 83655 | <1% | 15 | $260.33 | |
| 86706 | <1% | 64 | $258.23 | |
| 80177 | <1% | 52 | $253.31 | |
| 86376 | <1% | 12 | $251.75 | |
| 77073 | <1% | 18 | $236.28 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 279 | $218.49 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,428 | $218.22 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 1,354 | $211.20 |
| 86146 | <1% | 28 | $207.70 | |
| 84156 | <1% | 134 | $188.92 | |
| 83615 | <1% | 295 | $186.26 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,791 | $186.15 |
| 86003 | <1% | 26 | $179.84 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,766 | $173.76 |
| 87807 | <1% | 248 | $161.22 | |
| 85613 | <1% | 23 | $152.74 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 803 | $147.52 |
| 86704 | <1% | 27 | $140.59 | |
| 86256 | <1% | 20 | $140.03 | |
| 87046 | <1% | 218 | $132.49 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 508 | $127.62 |
| 86780 | <1% | 13 | $112.81 | |
| 51702 | <1% | 21 | $110.00 | |
| 83721 | <1% | 38 | $106.66 | |
| 86308 | <1% | 69 | $97.99 | |
| 80178 | <1% | 13 | $94.53 | |
| C1769 | Guide wire | <1% | 801 | $74.96 |
| 74022 | <1% | 21 | $73.08 | |
| 86920 | <1% | 39 | $72.25 | |
| 82310 | <1% | 103 | $63.39 | |
| 82010 | <1% | 314 | $51.75 | |
| 84165 | <1% | 16 | $49.83 | |
| 82248 | <1% | 259 | $46.87 | |
| 85046 | <1% | 48 | $40.45 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 550 | $38.44 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 740 | $36.80 |
| J1815 | Injection, insulin, per 5 units | <1% | 287 | $35.91 |
| 87493 | <1% | 35 | $33.54 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 830 | $28.30 |
| 87185 | <1% | 74 | $27.23 | |
| 80320 | <1% | 27 | $23.79 | |
| 85045 | <1% | 32 | $18.54 | |
| J7612 | Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 0.5 mg | <1% | 131 | $10.68 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 179 | $7.15 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 228 | $4.25 |
| 51798 | <1% | 138 | $2.54 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 122 | $1.84 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 28 | $1.38 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 286 | $0.96 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 413 | $0.49 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 233 | $0.37 |
| C1729 | Catheter, drainage | 0% | 158 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 29 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 565 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 293 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 322 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 122 | $0.00 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 187 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 210 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 47 | $0.00 |
| A4618 | Breathing circuits | 0% | 152 | $0.00 |
| J7614 | Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg | 0% | 18 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 52 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 89 | $0.00 |
| A6254 | Specialty absorptive dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | 0% | 12 | $0.00 |
| J1817 | Insulin for administration through dme (i.e., insulin pump) per 50 units | 0% | 283 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 276 | $0.00 |
| A4215 | Needle, sterile, any size, each | 0% | 13 | $0.00 |
| J8597 | Antiemetic drug, oral, not otherwise specified | 0% | 116 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 17 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 32 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 65 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 184 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 306 | $0.00 |
| C1755 | Catheter, intraspinal | 0% | 95 | $0.00 |
| 82330 | 0% | 54 | $0.00 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 15 | $0.00 |
| 82150 | 0% | 17 | $0.00 | |
| A6222 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 0% | 12 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 12 | $0.00 |
| 88307 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHANCOCK, MELINDA (CFO)
Parent organizationSENTARA HEALTHCARE
| Provider | Location | Paid |
|---|---|---|
| Sentara Hospitals | Norfolk, VA | $88.20M |
| Sentara Hospitals | Norfolk, VA | $79.69M |
| Sentara Hospitals | Hampton, VA | $78.52M |
| Potomac Hospital Corporation of Prince William | Woodbridge, VA | $59.17M |
| Sentara Hospitals | Suffolk, VA | $57.85M |
| Sentara Hospitals | Virginia Beach, VA | $52.40M |
| Sentara Princess Anne Hospital | Virginia Beach, VA | $37.50M |
| Martha Jefferson Hospital | Charlottesville, VA | $26.95M |
| Halifax Regional Hospital, INC. | South Boston, VA | $23.28M |
| Sentara Hospitals | Williamsburg, VA | $21.89M |
| Sentara Albemarle Regional Medical Center | Elizabeth City, NC | $13.82M |
| Sentara Reference Lab Solutions, LLC | Norfolk, VA | $4.74M |
| Halifax Regional Hospital, INC | South Boston, VA | $1.61M |
| Halifax Regional Hospital, INC | Nathalie, VA | $348K |
| Halifax Regional Hospital, INC | South Boston, VA | $336K |
| Halifax Regional Hospital, INC | Chase City, VA | $298K |
| Halifax Regional Hospital, INC | Clarksville, VA | $265K |
| Sentara Hospitals | Norfolk, VA | $171K |
| Halifax Regional Hospital, INC | South Boston, VA | $170K |
| Sentara Hospitals | Norfolk, VA | $128K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.